Our portfolio spans two clinical-stage programs built on validated mechanisms: direct AMPK activation in autosomal dominant polycystic kidney disease (ADPKD), and glucan synthase inhibition in serious and drug-resistant fungal infection. Guided by deep scientific expertise and disciplined development, we advance programs selected for the strength of their biology and the clarity of their path to patients.
SCYNEXIS develops therapies that target the biology driving severe rare disease, in indications where approved options are limited by tolerability or do not yet exist.
As cysts grow and kidney function declines, many patients with ADPKD eventually progress to end-stage renal disease. SCY-770 is designed to directly activate AMPK, targeting key metabolic pathways that contribute to disease progression, introducing a novel mechanism with the potential to change the treatment paradigm.
Serious, invasive and often deadly fungal infections treated in the hospital setting are increasingly drug resistant. Our first-in-class antifungal platform can give patients and healthcare professionals innovative new weapons to deploy against these dangerous diseases.
Our leadership team has successfully advanced therapies through clinical development, FDA approval, and global licensing transactions, bringing proven experience to every program in our portfolio.
Be part of a collaborative environment where your ideas, expertise, and passion can make a meaningful impact.